

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2026

Amesite Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39553
(Commission File Number)

82-3431718
(IRS Employer
Identification No.)

607 Shelby Street
Suite 700 PMB 214
Detroit, MI
(Address of principal executive offices)

48226
(Zip Code)

Registrant's telephone number, including area code: (734) 876-8141

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	AMST	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Amesite Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14, 2026, through September 16, 2026. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Presentation Materials – September 2026
104	Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMESITE INC.

Date: September 11, 2026

By: /s/ Ann Marie Sastry, Ph.D.

Name: Ann Marie Sastry, Ph.D.

Title: Chief Executive Officer



Shareholder Update

Q2 2027
September 9, 2026

© 2026 Amesite Inc. All Rights Reserved.

Forward Looking Statements

This presentation may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. As used below and throughout this presentation, the words “we”, “us” and “our” may refer to Amesite individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for and continued access to additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our Securities and Exchange Commission filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisions that apply to a given piece of information in one part of this presentation should be read as applying *mutatis mutandis* to every other instance of such information appearing herein.

Amesite builds AI-powered enterprise solutions for the \$1.5T* post-acute market

Fastest growing revenue is from larger enterprises. Outstanding reviews. 18 care segments.

Award-winning.

Recognized by McKnight's and Nurse.org in 2026.

50 states


Users across the United States.

21 countries

International user reach.


Outstanding reviews

5.0 App Store rating and 4.3 Google Play rating.



Home care · Hospice · Home health · Skilled nursing · Senior living · Assisted living · Nursing homes

From the B2C NurseMagic® App to Enterprise LynkMagic™ Solutions at Scale



From the B2C NurseMagic® App to Enterprise LynkMagic™ Solutions at Scale

2024 one clinician, one shift NurseMagic® B2C App

"I'm an NP and have been using NurseMagic® for about a month now. 5/5 stars! This has helped me so much in delivering exceptional care and writing nurse notes so much faster! I love NurseMagic® ❤️"

VOICE → STRUCTURED NOTE VIEW NOTE

Findings	Ambulation improved
Follow-up	14 days
Time	20 seconds

2025 tens of caregivers per buyer NurseMagic® B2B Platform

"The more a caregiver uses the tool, it's not just them conveying information back to us — it's them reading the information and becoming smarter. **That's why I tell you it's scalable.**"

DOCUMENTATION READINESS BY SITE

2,880 notes	93% complete
Cedar Valley	96%
Lakeshore	94%
Summit Ridge	88%

2025-26 2,700-patient census NurseMagic® B2B Platform + EMR


"It has been a night and day difference in getting documentation completed. This platform does not create a note or rehash the same verbiage that will compromise your documentation upon CMS review. Rather it assists the field staff in generating awesome narratives based upon **objective data.**"

VALUE TO OWNER EVERGREEN

24 communities	owner-level view
Value created	\$3.20M
After share & tax	\$1.96M

2026 LynkMagic™ LynkMagic™ Enterprise Solutions

"NurseMagic® is transformative for our organization and for the industry. NurseMagic® plugs straight into the systems we already use, and our documentation is faster and more accurate from day one. **We didn't have to change EMRs or disrupt our workflows to see the benefit, and we were up and running in minutes.**"



Growing Opportunity in Post-Acute and Adjacent Markets

Paying provider customers. Marketing to FMS organizations and REITs, with prospective buyers engaged.

PROVIDERS

\$389B annual care spending | 64,200 U.S. locations and agencies

Deliver care in homes and facilities.

Need AI to reduce paperwork and improve consistency across teams.

Buyer: Clinical, operations and compliance leaders.

Solution: AI documentation, compliance review and workforce training.

Value: More caregiver capacity. More complete records. Less rework.

Revenue: \$1,099/month minimum; \$1/person/month above approximately 1,100 people. Expand across locations and capabilities.

FMS — FINANCIAL MANAGEMENT SERVICES

1.5M+ Americans directing their own care

Administer payroll and program requirements for self-directed care.

Need AI to manage documentation across programs and states.

Buyer: Operations, program and compliance leaders.

Solution: AI form completion, state-form updates and reporting within existing portals.

Value: Less administrative work. More complete forms. Visibility across programs.

Revenue opportunity: Organization subscriptions, expanding across programs and states; pricing under development.

REITS — REAL ESTATE INVESTMENT TRUSTS

\$290B listed healthcare REIT sector equity value

Own properties where operators deliver care.

Need AI to connect operating data with portfolio decisions.

Buyer: Asset-management and portfolio leaders.

Solution: Shared performance reporting, with de-identified information for owners.

Value: Better resource allocation and spending decisions. Operating-portfolio owners can share in operator gains.

Revenue opportunity: Paid initial engagements, expanding across properties and operators; pricing under development.

Leadership and Team

FOUNDER AND CEO

Dr. Ann Marie Sastry

Founder, CEO, and Chair of the Board

- **Cornell PhD. University of Michigan professorship.** Arthur F. Thurnau Professor of Mechanical, Biomedical and Materials Science and Engineering.
- **100+ publications. 100+ patents and filings.** Research and invention across disciplines; 100+ invited lectures, including at MIT, Stanford, Berkeley, Oxford and Cambridge.
- **VC-backed exit. Nasdaq IPO.** Sakti3 acquired by Dyson. Amesite founded and taken public.
- **White House honors in science and entrepreneurship.** Presidential Early Career Award, 1997. Technology entrepreneurship recognition with President Barack Obama, 2015.
- **Recognition: Fields and Markets.** ASME Frank Kreith Energy Award. Sakti3 among MIT Technology Review's 50 Smartest Companies. McKnight's Commercial Excellence honoree, 2026.
- **>\$1M personally invested.** Personal capital committed alongside shareholders.

BOARD OF DIRECTORS

George Parmer

Founder across residential development, warranties and insurance; banking and university board leadership.

Barbie Brewer

Former talent and people executive at **Netflix, GitLab and Marqeta**. Experience building and scaling technology teams.

J. Michael Losh

Former CFO of **General Motors and Cardinal Health**. Board experience spanning Masco, Aon, H.B. Fuller and Prologis.

Dr. Gilbert S. Omenn, MD, PhD

Distinguished Michigan professor; global Human Proteome Project leader; former AAAS President. **27 years on Amgen's board.**

THE AMESITE TEAM

Decades of collective experience across the disciplines a modern AI company runs—from first-principles engineering to compliant production. Applied end to end, from model to deployment.

APPLIED SCIENCE & MODELING

- Computational modeling & simulation
- Numerical optimization
- Statistical inference
- Latency & performance engineering

AI SYSTEMS

- Model orchestration & routing
- Retrieval-augmented generation
- Streaming ASR & speech
- Structured extraction & NLP
- Evaluation harnesses & guardrails
- Fine-tuning & distillation

SOFTWARE & INFRASTRUCTURE

- Distributed systems
- Cloud architecture
- API & event pipelines
- Full-stack product engineering

SECURITY & COMPLIANCE

- Zero-trust access & IAM
- Encryption & key management
- De-identification
- HIPAA & multi-jurisdiction compliance

NurseMagic®: AI-Powered Documentation Solutions for Post-Acute Care Organizations



NurseMagic® brings AI documentation to every team

The screenshot displays the NurseMagic AI documentation interface. On the left, a sidebar shows a patient's care plan with various medical orders and interventions. The main area is titled "New Narrative" and includes a "How would you like to document?" section. Below this, there are two options: "New Narrative" (with a microphone icon) and "Resume a Saved Note" (with a circular arrow icon). The interface is clean and modern, with a light blue and white color scheme.

Nasdaq: AMST Infrastructure, Security and Compliance

EFFICIENCY AND INNOVATION ENABLE NEW PRODUCTS FOR AMST

AI-accelerated engineering, defined guardrails

AI-assisted development increases engineering throughput—delivering autonomously, 24/7, validated and reviewed for safety.

Continuous monitoring and improvement

Automated monitoring reduces the risk of bugs for customers and enables faster feature delivery.

Auditable and actionable

All production and user activity is continuously monitored for customers’ and Amesite’s own security.

COMPLIANCE AND DEPLOYABILITY ENABLE SEAMLESS CUSTOMER LAUNCHES

HIPAA compliant

Security and privacy controls are designed to support regulated healthcare environments.

Designed for frictionless DOH approval

Controls are designed to pass state Department of Health approvals on the first pass using rigorous, transparent standards.

100% U.S.-based delivery and data operations

- No offshore subcontractors or service personnel
- U.S.-hosted cloud infrastructure for Customer Data and PHI
- Rigorous background, exclusion and compliance screening
- Mandatory HIPAA, security and FWA training
- Least-privilege access with rapid deprovisioning and full auditability

NurseMagic®: AI-powered solutions for post-acute care

NurseMagic® and LynkMagic™ pricing is designed to provide high customer value, high AMST margin and ease of purchase.

PER SEAT

Individuals

For individual clinicians who want faster, more complete notes—dictated on their phone or the web, ready for review.

Priced per individual clinician

Free trial	7 days
Per clinician	\$7.99 /mo

For individuals

PER SITE

Facilities & agencies

For home health, hospice, home care, skilled nursing and senior-living operators standardizing across locations.

Census <1,000	\$1,099 /mo - flat
Census 1,000+	\$1 /census/mo
Census 10,000+	Custom

Book a Demo

PER PARTICIPANT

A LynkMagic™ Solution ↗

Fiscal intermediaries

For fiscal-intermediary and self-directed-care organizations operating documentation across many states at volume.

Scales by participant

Book a Demo

PER PARTICIPANT

A LynkMagic™ Solution ↗


Senior-living REITs & owners

Owner-level visibility: operator documentation as de-identified portfolio signal, valued to you after your share and tax.

Scales by participant

Book a Demo

NurseMagic®: AI-powered solutions for post-acute care



2025-Q4 to 2026-Q3 as reported. Earlier quarters shown to scale; exact figures pending.

yahoo/finance
May 19, 2026
NurseMagic® platform selected for large-scale healthcare deployment
Amesite Inc. (NASDAQ:AMST) shares soared 190% in premarket trading Tuesday after the company announced it had secured its largest enterprise customer so far, covering approximately 2,700 patients.

“We are supporting multiple roles, layered permissions, EMR and EVV integration. Because NurseMagic® is AI-first, automated, and configurable, we launch new customers quickly, without weeks or months of onboarding.”
Dr. Ann Marie Sastry, CEO and Founder, May 19, 2026

Nasdaq: AMST

April 2026 Capital Raise

\$2.6M

Total gross proceeds

\$1.435

Price per share

3

Concurrent tranches

\$5.2M

Potential warrant upside

Tranche	Participants	Securities Issued	Gross Proceeds
Registered Direct Offering	Institutional investors	696,866 shares of common stock at \$1.435/share (Form S-3 shelf)	~\$1.0M
Concurrent Private Placement	Institutional investors	Pre-funded warrants (696,866 sh) + Series A-1/A-2 warrants (1,393,732 sh each)	~\$1.0M
Insider-Led Placement	Chairman/CEO Dr. Ann Marie Sastry & director George Parmer	418,118 shares + Series A-1/A-2 warrants (418,118 sh each)	~\$0.6M

Nasdaq: AMST Financials Post Fundraise (4/28/26)

\$2.9M

Cash on hand

\$0

Debt

4.5M*

Public Float

16

Estimated months of burn on
hand, assuming no new revenue
(conservative)

6.5M*

Shares Outstanding

Market POV

| **Mature Infrastructure Enables AI:** AMST invested, tested, and delivered.

| **Differentiated Infrastructure from Legacy SAAS:** AMST delivers optionality on models. Superior traceability. Automated templating.

| **AI That Works Out of the Box:** AMST delivers products designed to launch in days.

| **Buildable, Operating Intelligence:** AMST delivers solutions more sophisticated than the ones it operates on.

| **Real Deployments:** AMST does not run pilots — deployments are production because the systems work with what is in place.

| **AI Means More Scrutiny:** AMST products are designed to reduce regulatory risk, with full auditability.

Amesite | Nasdaq: AMST

We are building the AI infrastructure for post-acute care, with paying enterprise customers and technology that works within existing systems.

Our opportunity is to expand across organizations as we solve more of their work, returning time to care and building recurring revenue.

Follow our progress. See what we're building.

amesite.com | nursemagic.ai | Investor updates: ir.amesite.com | X: @amesite
Facebook: facebook.com/amesiteinc